AMP Trademark
Trademark Overview
On Tuesday, January 16, 2024, a trademark application was filed for AMP with the United States Patent and Trademark Office. The USPTO has given the AMP trademark a serial number of 98360115. The federal status of this trademark filing is PUBLICATION/ISSUE REVIEW COMPLETE as of Monday, February 24, 2025. This trademark is owned by Advanced Medicine Partners, LLC. The AMP trademark is filed in the Treatment & Processing of Materials Services and Computer & Software Services & Scientific Services categories with the following description:
Biomanufacturing for others, namely, manufacturing of pharmaceuticals using biological organism in the manufacturing process; custom manufacture for others of products relating to biotechnology, namely, recombinant proteins for use in the biotechnology industries; custom manufacture for others of cell therapy products; custom manufacture for others of gene therapy products; custom manufacture of pharmaceuticals in accordance with specific standards GMP regulations
Contract development and manufacturing organization (CDMO) services, namely, pharmaceutical drug development services; consulting and advisory services in the field of analytical development and quality control testing of pharmaceutical, gene therapy, and cell therapy products; consulting and advisory services in the field of manufacturing process development for pharmaceutical, gene therapy and cell therapy products; consulting in the field of chemistry manufacturing and controls (CMC) activities; testing of pharmaceutical, gene therapy, and cell therapy products and materials; quality control testing of pharmaceutical products and materials, namely, biopharmaceutical products and materials in accordance with specifications or requirements of regulatory standards applicable in target countries; testing and validation services of biopharmaceutical products to assure compliance with global regulatory requirements, specifications, and industry standards for pharmaceutical, cell therapy a...
General Information
| Serial Number | 98360115 |
| Word Mark | AMP |
| Filing Date | Tuesday, January 16, 2024 |
| Status | 681 - PUBLICATION/ISSUE REVIEW COMPLETE |
| Status Date | Monday, February 24, 2025 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | Tuesday, March 18, 2025 |
Trademark Statements
| Goods and Services | Biomanufacturing for others, namely, manufacturing of pharmaceuticals using biological organism in the manufacturing process; custom manufacture for others of products relating to biotechnology, namely, recombinant proteins for use in the biotechnology industries; custom manufacture for others of cell therapy products; custom manufacture for others of gene therapy products; custom manufacture of pharmaceuticals in accordance with specific standards GMP regulations |
| Pseudo Mark | ADVANCED MEDICINE PARTNERS |
| Goods and Services | Contract development and manufacturing organization (CDMO) services, namely, pharmaceutical drug development services; consulting and advisory services in the field of analytical development and quality control testing of pharmaceutical, gene therapy, and cell therapy products; consulting and advisory services in the field of manufacturing process development for pharmaceutical, gene therapy and cell therapy products; consulting in the field of chemistry manufacturing and controls (CMC) activities; testing of pharmaceutical, gene therapy, and cell therapy products and materials; quality control testing of pharmaceutical products and materials, namely, biopharmaceutical products and materials in accordance with specifications or requirements of regulatory standards applicable in target countries; testing and validation services of biopharmaceutical products to assure compliance with global regulatory requirements, specifications, and industry standards for pharmaceutical, cell therapy and gene therapy methods of development; technical consulting for regulatory compliance in the field of chemistry manufacturing and controls (CMC) |
Classification Information
| International Class | 040 - Treatment of materials. |
| US Class Codes | 100, 103, 106 |
| Class Status Code | 6 - Active |
| Class Status Date | Monday, January 15, 2024 |
| Primary Code | 040 |
| First Use Anywhere Date | Monday, October 2, 2023 |
| First Use In Commerce Date | Monday, October 2, 2023 |
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Monday, January 15, 2024 |
| Primary Code | 042 |
| First Use Anywhere Date | Monday, October 2, 2023 |
| First Use In Commerce Date | Monday, October 2, 2023 |
Trademark Owner History
| Party Name | JAGUAR GENE THERAPY, LLC |
| Party Type | 11 - New Owner Before Publication |
| Legal Entity Type | 16 - Limited Liability Company |
| Address | LAKE FOREST, IL 60045 |
| Party Name | Advanced Medicine Partners, LLC |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 16 - Limited Liability Company |
| Address | Lake Forest, IL 60045 |
Trademark Events
| Event Date | Event Description |
| Tuesday, January 16, 2024 | NEW APPLICATION ENTERED |
| Monday, May 13, 2024 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Monday, August 12, 2024 | ASSIGNED TO EXAMINER |
| Friday, November 15, 2024 | APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED |
| Tuesday, August 20, 2024 | NON-FINAL ACTION E-MAILED |
| Tuesday, August 20, 2024 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Tuesday, August 20, 2024 | NON-FINAL ACTION WRITTEN |
| Friday, November 15, 2024 | APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED |
| Wednesday, February 5, 2025 | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP |
| Wednesday, February 19, 2025 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Wednesday, February 19, 2025 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Thursday, February 20, 2025 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Friday, February 21, 2025 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Wednesday, March 12, 2025 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
